[topsearch__bar__shortcode]

February 12, 2021

TLIS

Tonix Pharmaceuticals (TNXP) Continues to Rally after licensing Technology for Willi Syndrome

Tonix has licensed technology from the French National Institute of Health and Medical Research (Inserm). Shares of Tonix Pharmaceuticals (TNXP) have since the start of February 2021. On Monday, the shares soared over 22% following the announcement to develop a COVID-19 skin test. Once again, the stock is rolling, but this time with another important

Tonix Pharmaceuticals (TNXP) Continues to Rally after licensing Technology for Willi Syndrome Read More »